Literature DB >> 29600410

Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study.

Teppei Okamoto1, Shingo Hatakeyama2, Yoshimi Tanaka3, Kengo Imanishi3, Tooru Takashima3, Fumitada Saitoh3, Takuya Koie2, Tadashi Suzuki4, Chikara Ohyama2.   

Abstract

BACKGROUND: Erythropoiesis-stimulating agent (ESA) responsiveness is related to the nutritional status of patients on hemodialysis (HD). Serum butyrylcholinesterase (BChE), an alpha-glycoprotein, may decrease in case of malnutrition. We investigated whether BChE was independently related to ESA resistance in patients on HD.
METHODS: The laboratory data and ESA resistance index (ERI), defined as ESA dosage per week divided by dry weight and hemoglobin, were investigated in 215 patients on HD between July and September 2017. Malnutrition was defined as Geriatric Nutritional Risk Index (GNRI) of < 91.2. The patients were stratified into two groups: ERI-high (ERI ≥ 9.44) and ERI-low (ERI < 9.44) groups. Variables such as patient's background, medication, and laboratory data were compared between the two groups. The optimal cutoff value of BChE for higher ERI was determined using receiver operating characteristic analysis. Factors independently associated with higher ERI were determined using multivariate logistic regression analysis.
RESULTS: The median and optimal cutoff values of ERI and BChE were 6.51 and 200 IU/L, respectively. The study included 71 (33%) and 144 (67%) patients in the ERI-high and ERI-low groups, respectively. Significant between-group differences were observed concerning age, hemoglobin, ESA dose, lipid profiles, serum albumin, body mass index, GNRI, iron metabolism markers, ferric medicines, and BChE. Multivariate analysis showed that BChE < 200 IU/L (odds ratio 3.67; 95% confidence interval 1.73-7.77) continued to be an independent factor associated with higher ERI after adjusting for potential confounders, which was a similar odds ratio as GNRI < 91.2.
CONCLUSION: BChE may be an independent indicator of ESA resistance.

Entities:  

Keywords:  Butyrylcholinesterase; Erythropoiesis-stimulating agent resistance; Erythropoietin; Geriatric Nutritional Risk Index; Hemodialysis

Mesh:

Substances:

Year:  2018        PMID: 29600410     DOI: 10.1007/s10157-018-1569-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  33 in total

1.  Half-life of plasma cholinesterase.

Authors:  D Ostergaard; J Viby-Mogensen; H K Hanel; L T Skovgaard
Journal:  Acta Anaesthesiol Scand       Date:  1988-04       Impact factor: 2.105

2.  Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients.

Authors:  Olivier Bouillanne; Gilles Morineau; Claire Dupont; Isabelle Coulombel; Jean-Pierre Vincent; Ioannis Nicolis; Simone Benazeth; Luc Cynober; Christian Aussel
Journal:  Am J Clin Nutr       Date:  2005-10       Impact factor: 7.045

3.  Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters.

Authors:  H Schiffl; S M Lang; D Stratakis; R Fischer
Journal:  Nephrol Dial Transplant       Date:  2001-09       Impact factor: 5.992

4.  Serum cholinesterase activity correlates with serum insulin, C-peptide and free fatty acids levels in patients with type 2 diabetes.

Authors:  M Cucuianu; T Nistor; N Hâncu; P Orbai; Corina Muscurel; Irina Stoian
Journal:  Rom J Intern Med       Date:  2002

5.  Interleukin-6 may mediate malnutrition in chronic hemodialysis patients.

Authors:  Y Kaizu; M Kimura; T Yoneyama; K Miyaji; I Hibi; H Kumagai
Journal:  Am J Kidney Dis       Date:  1998-01       Impact factor: 8.860

Review 6.  Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach.

Authors:  Diego Brancaccio; Mario Cozzolino; Maurizio Gallieni
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

7.  Butyrylcholinesterase activity is reduced in haemodialysis patients: is there association with hyperhomocysteinemia and/or oxidative stress?

Authors:  Solange C Garcia; Angela T S Wyse; Juliana Valentini; Miguel Roehrs; Angela M Moro; Clóvis Paniz; Gabriela Schmitt; Denise Grotto; Valdeci J Pomblum
Journal:  Clin Biochem       Date:  2008-01-16       Impact factor: 3.281

8.  Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Authors:  Ryan D Kilpatrick; Cathy W Critchlow; Steven Fishbane; Anatole Besarab; Catherine Stehman-Breen; Mahesh Krishnan; Brian D Bradbury
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 8.237

9.  Effects of a new mixture of essential amino acids (Aminotrofic(®)) in malnourished haemodialysis patients.

Authors:  S G Sukkar; F Gallo; C Borrini; A Vaccaro; C Marchello; R Boicelli; C Borgarelli; P Solari; C E Ratto; G Ravera
Journal:  Med J Nutrition Metab       Date:  2012-06-22

10.  Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS.

Authors:  Tadao Akizawa; Ronald L Pisoni; Takashi Akiba; Akira Saito; Shunichi Fukuhara; Yasushi Asano; Takeshi Hasegawa; Friedrich K Port; Kiyoshi Kurokawa
Journal:  Nephrol Dial Transplant       Date:  2008-06-24       Impact factor: 5.992

View more
  2 in total

1.  Low serum butyrylcholinesterase is independently related to low fetuin-A in patients on hemodialysis: a cross-sectional study.

Authors:  Teppei Okamoto; Chikako Tsutaya; Shingo Hatakeyama; Sakae Konishi; Kazutaka Okita; Yoshimi Tanaka; Kengo Imanishi; Tooru Takashima; Fumitada Saitoh; Tadashi Suzuki; Chikara Ohyama
Journal:  Int Urol Nephrol       Date:  2018-08-20       Impact factor: 2.370

2.  Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study.

Authors:  Akinori Hara; Yoshitaka Koshino; Yukie Kurokawa; Yasuyuki Shinozaki; Taito Miyake; Shinji Kitajima; Tadashi Toyama; Yasunori Iwata; Norihiko Sakai; Miho Shimizu; Kengo Furuichi; Hiroyuki Nakamura; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2019-09-09       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.